Patents Assigned to University of Iceland
-
Publication number: 20230040736Abstract: The present invention relates to novel organic dinitroxide biradical compounds and their use as polarizing agents, in particular, in the techniques of Nuclear Magnetic Resonance (NMR) of solids or liquid samples and medical imaging.Type: ApplicationFiled: July 18, 2022Publication date: February 9, 2023Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, University of IcelandInventors: Gaël De Paepe, Frédéric Mentink-Vigier, Snorri Sigurdsson, Anil Jagtap
-
Patent number: 11472790Abstract: The present invention relates to novel organic dinitroxide biradical compounds and their use as polarizing agents, in particular, in the techniques of Nuclear Magnetic Resonance (NMR) of solids or liquid samples and medical imaging.Type: GrantFiled: July 3, 2018Date of Patent: October 18, 2022Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, University of IcelandInventors: Gaël De Paepe, Frédéric Mentink-Vigier, Snorri Sigurdsson, Anil Jagtap
-
Publication number: 20200148666Abstract: The present invention relates to novel organic dinitroxide biradical compounds and their use as polarizing agents, in particular, in the techniques of Nuclear Magnetic Resonance (NMR) of solids or liquid samples and medical imaging.Type: ApplicationFiled: July 3, 2018Publication date: May 14, 2020Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, University of IcelandInventors: Gaël De Paepe, Frédéric Mentink-Vigier, Snorri Sigurdsson, Anil Jagtap
-
Patent number: 10557861Abstract: Disclosed herein are methods, biomarkers, systems, compositions and kits for determining the phase or metabolic state (e.g. First Phase, Second Phase, or Third Phase) of a red blood cell (RBC) sample or for determining the phase or metabolic state (e.g., First Phase or Second Phase) of a platelet (PLT) cell sample. The methods disclosed herein are related to the use of isolated RBC sample or isolated PLT sample and analytical tools for providing information that is relevant to the phase or metabolic state of the RBC sample or the PLT sample. The system disclosed herein utilizes isolated RBC sample or isolated PLT sample and at least one analytical tool or an output from the at least one analytical tool. The compositions and kits described herein utilize RBC samples or PLT samples, including compositions in a form that allows for analysis of the RBC sample or the PLT sample.Type: GrantFiled: May 15, 2015Date of Patent: February 11, 2020Assignee: UNIVERSITY OF ICELAND, CENTER FOR SYSTEMS BIOLOGYInventors: Giuseppe Paglia, Sirus Palsson, Aarash Bordbar
-
Patent number: 10391722Abstract: The invention provides a method of molding composite material aerofoil, comprising steps of (i) providing a mold having the desired three-dimensional shape; (ii) providing a first layer over the mold that adheres to the mold and has a non-adhesive outer surface; (iii) applying composite material over the first layer; (iv) laying a moldable sheet over the composite material; (v) curing the resulting assembly and (vi) removing the moldable sheet and mold to leave an intact one-piece aerofoil structure.Type: GrantFiled: July 12, 2017Date of Patent: August 27, 2019Assignee: UNIVERSITY OF ICELANDInventors: Solrun Traustadottir, Andri Orrason
-
Patent number: 10052333Abstract: The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal.Type: GrantFiled: May 25, 2017Date of Patent: August 21, 2018Assignee: UNIVERSITY OF ICELANDInventor: Sveinbjorn Gizurarson
-
Patent number: 9687495Abstract: The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal.Type: GrantFiled: February 10, 2016Date of Patent: June 27, 2017Assignees: HANANJA EHF, UNIVERSITY OF ICELANDInventor: Sveinbjorn Gizurarson
-
Patent number: 9289432Abstract: The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal.Type: GrantFiled: July 14, 2014Date of Patent: March 22, 2016Assignee: HANANJA EHF and UNIVERSITY OF ICELANDInventor: Sveinbjorn Gizurarson
-
Patent number: 8809322Abstract: The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal.Type: GrantFiled: April 13, 2012Date of Patent: August 19, 2014Assignees: Hananja EHF, University of IcelandInventor: Sveinbjorn Gizurarson
-
Publication number: 20140031274Abstract: The present invention relates to the biological and pharmacological effects of placental protein 13 (PP-13), an effect that may be used as a treatment and/or prevention of preeclampsia and placental insufficiencies, in pregnant female mammals, especially pregnant women. The invention relates to a method to treat female mammals with the purpose to precondition the uterine arteries and prevent and/or reverse the pathological conditions associated with placental insufficiency such as preeclampsia, HELLP and/or eclampsia.Type: ApplicationFiled: December 14, 2011Publication date: January 30, 2014Applicants: UNIVERSITY OF ICELAND, HANANJA EHFInventors: Sveinbjorn Gizurarson, Hamutal Meiri
-
Publication number: 20120264745Abstract: The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal.Type: ApplicationFiled: April 13, 2012Publication date: October 18, 2012Applicants: University of Iceland, Hananja ehfInventors: Sveinbjorn Gizurarson, James Arp, Raouf Ghaderi, Michael E. Lusty, Gregory G. Plucinski, Mehdi Yazdi
-
Patent number: 8217033Abstract: The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal.Type: GrantFiled: May 20, 2009Date of Patent: July 10, 2012Assignees: Hananja EHF, University of IcelandInventor: Sveinbjorn Gizurarson